title: Depo-Provera and Norplant implants prove no competition for no. 1 choice, OCs. The 1994 pill survey.
mesh_terms: D000554:Ambulatory Care Facilities; D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003376:Counseling; D003695:Delivery of Health Care; D019049:Developed Countries; D004194:Disease; D005193:Family Planning Services; D006262:Health; D006282:Health Personnel; D006285:Health Planning; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D008599:Menstruation Disturbances; D009656:North America; D013812:Therapeutics; D014481:United States
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate
keywords: Americas; Clinic Activities; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Implants; Contraceptive Methods--side effects; Counseling; Delivery Of Health Care; Depo-provera--side effects; Developed Countries; Diseases; Family Planning; Family Planning Surveys; Health; Health Personnel; Insertion; Levonorgestrel--side effects; Medroxyprogesterone Acetate--side effects; Menstruation Disorders; North America; Northern America; Oral Contraceptives, Combined--side effects; Oral Contraceptives--side effects; Program Activities; Programs; Research Report; Treatment; United States